Hemogenyx Pharmaceuticals (LON:HEMO) Shares Down 15.4% - Here's Why

Key Points

• Shares of Hemogenyx Pharmaceuticals (LON:HEMO) fell by 15.4%, trading as low as GBX 940 ($12.55) during mid-day trading on Friday.
• The company's trading volume increased by 191% from the average, with 189,127 shares traded compared to the usual 64,973.
• Hemogenyx Pharmaceuticals is a preclinical-stage biotechnology company developing therapies for blood diseases, including products for bone marrow transplant markets.

Hemogenyx Pharmaceuticals Plc (LON:HEMO - ) fell 15.4% during mid-day trading on Friday . The company traded as low as GBX 940 ($12.55) and last traded at GBX 1,070 ($14.28). 189,127 shares were traded during trading, an increase of 191% from the average session volume of 64,973 shares. The stock had previously closed at GBX 1,265 ($16.88).

Hemogenyx Pharmaceuticals Price Performance

The company's 50 day simple moving average is GBX 520.66 and its 200 day simple moving average is GBX 293.39. The company has a debt-to-equity ratio of 90.87, a current ratio of 4.38 and a quick ratio of 6.72. The stock has a market cap of £51.05 million, a P/E ratio of -596.36 and a beta of 3.14.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.